Pioglitazone hydrochloride

PAT-505 is a potent, selective, noncompetitive and orally available autotaxin inhibitor, with an IC 50 of 2 nM in Hep3B cells, 9.7 nM in human blood and 62 nM in mouse plasma.In VitroPAT-505 is a potent, selective, noncompetitive and orally

PAT-505 is a potent, selective, noncompetitive and orally available autotaxin inhibitor, with an IC 50 of 2 nM in Hep3B cells, 9.7 nM in human blood and 62 nM in mouse plasma.In VitroPAT-505 is a potent, selective, noncompetitive and orally

PAT-505 is a potent, selective, noncompetitive and orally available autotaxin inhibitor, with an IC 50 of 2 nM in Hep3B cells, 9.7 nM in human blood and 62 nM in mouse plasma.In VitroPAT-505 is a potent, selective, noncompetitive and orally

PAT-505 is a potent, selective, noncompetitive and orally available autotaxin inhibitor, with an IC 50 of 2 nM in Hep3B cells, 9.7 nM in human blood and 62 nM in mouse plasma.In VitroPAT-505 is a potent, selective, noncompetitive and orally

A highly potent, reversible inhibitor of the EGFR (Ki = 5.2 pM IC₅₀ = 29 pM) rapidly suppresses autophosphorylation of EGFR in ?broblasts and human epidermoid carcinoma cells.

A reversible inhibitor of the auto and transphosphorylation kinase activity of the ErbB receptor tyrosine kinase superfamily: EGFR (IC₅₀ = 8 &microM), ErbB-2 (IC₅₀ = 49 nM), ErbB3, and ErbB4 (IC₅₀ = 52 nM) induces

PD153035 is a potent and specific inhibitor of EGFR with Ki and IC50 of 5.2 pM and 29 pM: little effect noted against PGDFR, FGFR, CSF-1, InsR and Src.A potent inhibitor of epidermal growth factor (EGF) receptor tyrosine kinase.

Introduction:PF-04418948 is an orally active, potent and selective prostaglandin EP2 receptor antagonist with an IC50 of 16 nM.

Introduction:PF-04418948 is an orally active, potent and selective prostaglandin EP2 receptor antagonist with an IC50 of 16 nM.

Introduction:PF-04418948 is an orally active, potent and selective prostaglandin EP2 receptor antagonist with an IC50 of 16 nM.

Introduction:PF-04418948 is an orally active, potent and selective prostaglandin EP2 receptor antagonist with an IC50 of 16 nM.

PF-5006739 is a potent and selective inhibitor of CK1δ/ε with IC50s of 3.9 nM and 17.0 nM, respectively. PF-5006739 is a potential therapeutic agent for a range of psychiatric disorders with low nanomolar in vitro potency for CK1δ/ε and high kinome